Komunikaty PR

G7 LEADERS URGED TO STRENGTHEN BRAIN HEALTH TO BOOST ECONOMIC GROWTH AND STABILIZE HEALTH COSTS

2025-06-13  |  14:55:03

As the cost of brain conditions is expected to balloon to $16 trillion by 2030, G7 leaders and Canada are uniquely positioned to deliver solutions.

No nation can afford to ignore the multi-trillion-dollar cost of unaddressed brain disorders. The G7 has an opportunity to solve this crisis to create a global brain economy.”
— George Vradenburg, Founding Chairman of the Davos Alzheimer’s Collaborative
CALGARY, ALBERTA, CANADA, June 13, 2025 /EINPresswire.com/ -- A growing international coalition of scientific, business, and policy leaders has issued a declaration calling on G7 leaders to adopt a policy roadmap that will deliver sustained progress on brain health through the 2026 G7 Leaders' Summit in France.

The Canada Brain Economy Declaration builds on the expanding body of evidence that an erosion of brain health represents an imminent crisis that could cripple major economies if businesses, health systems, and governments do not adopt transformative and coordinated solutions.

The recommendations will be made public during the G7 Canada Brain Economy Summit in Calgary on June 14. They outline concrete steps G7 leaders can take in 2025 to prioritize the creation of a global brain economy—one that will power a more resilient, productive future fueled by healthy brains to meet the rising demand for brain capital.

Sustainable economic growth and human development depend on brain capital—a combination of brain health and brain skills that is rapidly emerging as a key driver of competitive advantage. Realizing its full potential will require nations to support healthy brain function across the workforce, address conditions such as mental, neurological, and substance use disorders, and promote brain skills like creativity, emotional regulation, and adaptability.

The core recommendations included in the Canada Brain Economy Declaration are:

i) Instruct Finance and Health Ministers to develop a coordinated plan to accelerate the brain economy, including concrete investment and policy proposals

ii) Establish a G7+ Brain Economy Working Group to align efforts across countries and sectors

iii) Convene a G7 Brain Economy Conference to scale proven solutions and forge new partnerships

iv) Include brain capital in the 2025 Leaders’ Communiqué, positioning it as central to economic stability and innovation

“Governments are treating human brain health as an economic cost, not as an asset that can be harnessed for significant competitive and societal advantage,” said Jennie Z. Young, PhD, Executive Director of the Canadian Brain Research Strategy. “There is momentum across all sectors in Canada and other nations. But without G7 leadership, we won’t unlock the full economic potential that can be harnessed by investing in brain capital initiatives.”

“Brain health is foundational to our future economy, especially as aging populations and the rise of neurodegenerative and mental health disorders threaten national fiscal stability,” said George Vradenburg, Founding Chairman of the Davos Alzheimer’s Collaborative. “No nation can afford to ignore the multi-trillion-dollar cost of unaddressed brain disorders. This is higher than the annual GDP of Germany, France, Italy, and the UK combined. The G7 has a unique opportunity to solve this crisis, joining the private sector and civil society to create a global brain economy.”

The economic burden of brain and mental health conditions is mounting. In G7 countries, these conditions are now the leading cause of disability and a major driver of lost productivity. Yet government investment and policy coordination remain decades behind the scale of the crisis—leaving people and economies vulnerable. Brain health includes mental, neurological, and substance use disorders that affect individuals across all life stages—from early childhood and adolescence to working-age adults and older populations.

The Declaration makes clear that this is not simply a health or aging issue: It is a business and labor issue that drives national competitiveness and global economic growth. G7 countries have strong, educated workforces, but they are failing to convert that potential into productivity gains. In Canada, for example, GDP per capita has declined for three consecutive years despite having the largest proportion of working-age people in the G7. That mismatch, the Declaration argues, is the brain economy gap.

The push for coordinated action is gaining ground. In September, global stakeholders will reconvene at a high-level side event hosted by the European Brain Council (EBC) during the Science Summit at the 80th United Nations General Assembly (UNGA80) in New York. The event, organized under the banner of the Global Brain Coalition, will continue the work of shaping a shared, global response to the erosion of brain capital. This G7 Canada work will also be integrated into the World Economic Forum’s (WEF) Brain Economy Action Forum and Insights Report to be published at the January 2026 WEF Annual Meeting.

“The future of brain health depends on international cooperation,” said Frédéric Destrebecq, EBC Executive Director. “At UNGA80, we are bringing together voices from science, policy, civil society, and industry to shape a global response to one of the century’s greatest health challenges.”

The Summit is also part of the Davos Alzheimer’s Collaborative Brain House Tour, a global initiative launched at the 2025 World Economic Forum. Each stop convenes leaders from science, business, and policy to shape the systems-level change needed to reduce the burden of brain conditions and build the brain capital required for future generations. The tour will culminate in the release of a global roadmap at Davos 2026.

G7 leaders have a precedent for this kind of action. Past summits have led global responses to pandemics, antimicrobial resistance, and financial instability. The erosion of brain capital is another systemic risk—but this one is preventable. The Declaration urges leaders to act now—and to commit to sustained progress through the 2026 G7 Summit in France.

About the Canada Brain Economy Declaration

The Canada Brain Economy Declaration represents the culmination of a months-long effort that brought together more than 100 senior global leaders from government, business, research, and civil society through a series of roundtables, consultations, and convenings aligned with the 2025 G7 Leaders’ Summit.

The effort was convened by the Alzheimer’s Society of Montreal, Canadian Brain Research Strategy, Centre for Aging + Brain Health Innovation, Davos Alzheimer’s Collaborative, European Brain Council, Hotchkiss Brain Institute, Ontario Brain Institute, Rice University, and the University of Calgary.

We also gratefully acknowledge the hundreds of other individuals and organizations—across sectors and borders—whose thought leadership, time, and collaboration helped shape this global movement and the Declaration it has produced.

Lindsay Borthwick
Canadian Brain Research Strategy
+1 416-706-7522
email us here
Visit us on social media:
LinkedIn
Bluesky
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, firmy czy instytucje państwowe.
Ostatnio dodane
komunikaty PR z wybranej przez Ciebie kategorii
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 04:55:04

DXRacer, 전설적인 저격수 kennyS와 손잡고 e스포츠 역사의 새로운 장을 열다

KennyS X DXRACER CollaborationMartian ProKennyS Legend SniperDXRACER— 장인정신으로 클래식을 기리고, 혁신을 통해 미래를 포용하다SEOUL, SOUTH KOREA, June 17, 2025 /EINPresswire.com/ -- [전설적인 동맹: 최고의
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

NEXCOM EBC 370 Powers Autonomous Robotics for Industrial Applications

Highly Efficient, Edge AI Computing Delivered in a Compact New CPUThe EBC 370/EBC 370X is an AI-powered, PC-based controller designed to adapt to the most demanding conditions. Research labs use it as the main control unit for advanced robotics
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

The End Brain Cancer Initiative Partners with Curis to Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial

The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial REDMOND, WA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE Contact: Dellann Elliott Mydland, 425-785-8489, Dellann@EndBrainCancer.org The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial The End Brain Cancer Initiative (EBCI) has partnered with Curis to promote awareness and pre-qualify patients for the company’s TakeAim Lymphoma Clinical Trial (CA-4948-101) clinical trial, an open-label, dose escalation and expansion trial of Emavusertib in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/​R PCNSL) (NCT03328078). “We are proud to partner with the End Brain Cancer Initiative to help raise awareness for primary CNS lymphoma (PCNSL), a rare and challenging form of cancer non-Hodgkin lymphoma. Together, we aim to highlight the unmet medical needs of this patient community, provide relevant resources to patients and their care providers, along with increasing awareness of clinical trials,” shared the Chief Medical Officer of Curis Inc, Ahmed Hamdy, MD. “Curis is committed to developing emavusertib for the treatment of PCNSL and broader non-Hodgkin lymphoma indications.” Patients who would like to learn more about this clinical trial and see if they qualify can visit https://endbraincancer.org/curis-therapeutics/ or contact the End Brain Cancer Initiative’s Clinical Research Coordinator and Patient Navigator, Shreya Prakash, at Shreya@EndBrainCancer.org or 425-436-8688. About Curis Curis, located in Lexington, Massachusetts, is a biotechnology company focused on the development of Emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to Emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at https://www.curis.com/. About the End Brain Cancer Initiative To support/donate to the End Brain Cancer Initiative’s increased access and health delivery for patients, mission, services and programs, please visit EndBrainCancer.org The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, outreach, increasing patient access and improving Standard of Care. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with their medical teams. Learn more about the End Brain Cancer Initiative or how to sponsor this annual campaign at EndBrainCancer.org. Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489, Dellann@EndBrainCancer.org

Kalendarium

Więcej ważnych informacji

Jedynka Newserii

Jedynka Newserii

Kongres Profesjonalistów Public Relations

Ochrona środowiska

Z powodu braku przejrzystego prawa branża recyklingu odkłada inwestycje. Firmy apelują o szybkie wdrożenie przepisów

Branża recyklingu stoi przed wyzwaniami związanymi z wdrożeniem systemu kaucyjnego, systemu rozszerzonej odpowiedzialności producenta i rozporządzenia PPWR. Brakuje jednak odpowiednich przepisów dostosowujących polskie prawo i realia do unijnych regulacji. W efekcie utrzymującej się niepewności prawnej między 2018 a 2023 rokiem co trzeci zakład recyklingu zamknął działalność. Wiele firm odkłada inwestycje, czekając na uregulowanie rynku. Podobna niepewność dotyczy też producentów opakowań. 

Transport

Testowanie pojazdów zautomatyzowanych wkrótce będzie możliwe. To odpowiedź na postulaty przedsiębiorców

Kończą się prace nad przepisami, które mają usprawnić prace badawcze nad pojazdami zautomatyzowanymi. Ma to być odpowiedź na postulaty przedsiębiorców, którzy wskazywali na potrzebę pilnej zmiany przepisów w zakresie testowania pojazdów autonomicznych. Obecne regulacje nie sprzyjają postępowi technologicznemu i rozwoju autonomiczności pojazdów, o czym świadczy bardzo niewielka liczba wydanych uprawnień do ich prowadzenia.

Firma

Przedsiębiorcom coraz bardziej doskwiera niestabilność i skomplikowanie przepisów podatkowych. Problemem są też niejasne ich interpretacje

Polscy przedsiębiorcy często negatywnie oceniają jakość przepisów podatkowych – wynika z raportu „Przedsiębiorcy pod lupą fiskusa 2025” przygotowanego przez firmę doradztwa podatkowego MDDP we współpracy z Konfederacją Lewiatan. Ich niepokój budzą niejednolite interpretacje przepisów i niepewność prawa podatkowego, które cały czas jest modyfikowane. Wśród kluczowych zmian w obszarze podatków, które będą dotyczyć praktycznie wszystkich przedsiębiorców, są m.in. wprowadzenie Krajowego Systemu e-Faktur czy zmiany w podatku od nieruchomości.

Partner serwisu

Instytut Monitorowania Mediów

Szkolenia

Akademia Newserii

Akademia Newserii to projekt, w ramach którego najlepsi polscy dziennikarze biznesowi, giełdowi oraz lifestylowi, a  także szkoleniowcy z wieloletnim doświadczeniem dzielą się swoją wiedzą nt. pracy z mediami.